The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma

Autor: Peter Browett, Kim Linton, Fontanet Bijou, Keshu Zhou, Chris Tankersley, Massimo Cappellini, Melannie Co, Pamela McKay, Eliza A Hawkes, Xiaoyan Ke, Jane Huang, Catherine Thieblemont, Shir-Jing Ho, Robert Marcus, Morton Coleman, Patricia F. Walker, Magdalena Sobieraj-Teague, Alessandra Tedeschi, Sally Mapp, Bei Hu, Dipti Talaulikar, Jie Jin, Stephen Opat, Mingyuan Sun, Craig A. Portell, Pier Luigi Zinzani, Judith Trotman, Xiaotong Li, Kirit M. Ardeshna, Wenxiao Zhou, Henry Chan

Publikováno v: Opat, S, Tedeschi, A, Linton, K, McKay, P, Hu, B, Chan, H, Jin, J, Sobieraj-Teague, M, Zinzani, P L, Coleman, M, Thieblemont, C, Browett, P, Ke, X, Sun, M, Marcus, R, Portell, C A, Ardeshna, K, Bijou, F, Walker, P, Hawkes, E A, Mapp, S, Ho, S J, Talaulikar, D, Zhou, K S, Co, M, Li, X, Zhou, W, Cappellini, M, Tankersley, C, Huang, J & Trotman, J 2021, ' The MAGNOLIA Trial : Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma ', Clinical Cancer Research, vol. 27, no. 23, pp. 6323-6332 . https://doi.org/10.1158/1078-0432.CCR-21-1704

Purpose: Marginal zone lymphoma (MZL) is an uncommon non–Hodgkin lymphoma with malignant cells that exhibit a consistent dependency on B-cell receptor signaling. We evaluated the efficacy and safety of zanubrutinib, a next-generation selective Brut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c77e8351212447450b1a1b606df0a8d9
https://doi.org/10.1158/1078-0432.ccr-21-1704